SQZ Biotechnologies Co
OTC:SQZB
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
SQZ Biotechnologies Co
OTC:SQZB
|
708k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.3B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
73.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.1B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
SQZ Biotechnologies Co
Glance View
SQZ Biotechnologies Co. is a clinical-stage biotechnology company, which engages in developing cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company is headquartered in Watertown, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2020-10-30. The firm is developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company uses its technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. Its SQZ Antigen Presenting Cells (SQZ APC) platform is in a Phase I trial in human papillomavirus (HPV) plus tumors. The company is also developing SQZ Activating Antigen Carriers (SQZ AAC) and SQZ Tolerizing Antigen Carriers (SQZ TAC). Its SQZ APC platform is focused on generating cluster of differentiation 8 (CD8) plus T cell responses. Its lead product candidate, SQZ- peripheral blood mononuclear cells (PBMC)-HPV, from its SQZ APC platform, is a targeted cancer vaccine that is designed to generate antigen-specific CD8 plus T cell responses to attack HPV plus tumors.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for SQZ Biotechnologies Co is -591.2%, which is below its 3-year median of -484.7%.
Over the last 2 years, SQZ Biotechnologies Co’s Net Margin has decreased from -346.3% to -591.2%. During this period, it reached a low of -591.2% on Sep 30, 2023 and a high of -253.7% on Dec 31, 2021.
